SHULTS Gregor (DE),ШУЛЬЦ Грегор (DE),OSTERROT Frank (DE),ОСТЕРРОТ Франк (DE),KHEDER Tomas (DE),ХЕДЕР Томас (DE),BRYUKHER Kristof (DE),БРЮХЕР Кристоф (DE),NIMANN Gabriele (DE),НИМАНН Габриэле (DE),ENGL,SHULTS Gregor,ШУЛЬЦ Грегор,OSTERROT Frank,ОСТЕРРОТ Франк,KHEDER Tomas,ХЕДЕР Томас,BRYUKHER Kristof,БРЮХЕР Кристоф,NIMANN Gabriele,НИМАНН Габриэле,ENGLING Andre,ЭНГЛИНГ Андре,UEREK Kristof,УЭРЕК Кристо
申请号：
RU2014127298
公开号：
RU0002632108C2
申请日:
2012.12.07
申请国别(地区):
RU
年份:
2017
代理人:
摘要：
FIELD: medicine.SUBSTANCE: method of treating a disease comprises administering to a human an immunoconjugate comprising at least one engineered targeting antibody targeted by cells expressing CD138 and at least one effector molecule, wherein said engineered targeting antibody is operably linked to said effector molecule to form mentioned immunoconjugate. A portion of the designed targeting antibody imparts IgG4 isotype characteristics, wherein the engineered targeting antibody comprises: (i) a heavy chain having at least 85% sequence identity with SEQ ID NO: 1, wherein the heavy chain comprises a variable region containing amino acid residues 31-35 (CDR1), 51-68 (CDR2) and 99-111 (CDR3) of SEQ ID NO: 1, and (ii) a light chain having at least 85% sequence identity with SEQ ID NO: 2, wherein the light chain comprises a variable A region containing amino acid residues 24-34 (CDR1), 50-56 (CDR2), and 89-97 (CDR3) of the sequence of SEQ ID NO: 2. The effector molecule is a maytansinoid. The immunoconjugate is administered in a cycle of active treatment lasting 21 days, at least three times within the indicated 21 days. The mentioned active treatment cycle comprises the mentioned administration, performed at least once a week, wherein the immunoconjugate is administered at least once a week at a dose of 80 mg/m2 Up to 120 mg/m2. The group of inventions also relates to a kit for treating a disease associated with target cells expressing CD138.EFFECT: use of this group of inventions allows for the introduction of higher doses of immunoconjugate in a multiple-dose regimen with allowance for the limiting toxicity.23 cl, 38 dwg, 24 tbl, 4 exГруппа изобретений относится к медицине, а именно к иммунологии, и может быть использовано для способа лечения заболевания, связанного с клетками-мишенями, экспрессирующими CD138. Способ лечения заболевания включает введение человеку иммуноконъюгата, содержащего по крайней мере одно сконструированное нацеливающее антитело, мишенями которог
